Literature DB >> 10214548

The methadone-maintained pregnancy.

S R Kandall1, T M Doberczak, M Jantunen, J Stein.   

Abstract

Methadone treatment during pregnancy offers overwhelming advantages compared with the less acceptable option of medical detoxification or the unacceptably dangerous option of leaving heroin-addicted women dependent on street drugs. General agreement exists that pregnancy offers a unique opportunity to bring women into medical, obstetric, and drug treatment. Methadone maintenance in the setting of comprehensive service provision during pregnancy reduces maternal morbidity and mortality and promotes fetal stability and growth. With an accumulated experience of over 25 years, methadone maintenance has been shown to be an invaluable and often an essential ingredient in bettering the health of women during pregnancy, in improving the outcomes of those pregnancies, and in offering opiate-addicted women a chance to improve both their lives and the lives of their families.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10214548

Source DB:  PubMed          Journal:  Clin Perinatol        ISSN: 0095-5108            Impact factor:   3.430


  16 in total

1.  Use of methadone.

Authors:  I B Anderson; T E Kearney
Journal:  West J Med       Date:  2000-01

Review 2.  The pharmacological treatment of opioid addiction--a clinical perspective.

Authors:  Philipp Lobmaier; Michael Gossop; Helge Waal; Jorgen Bramness
Journal:  Eur J Clin Pharmacol       Date:  2010-02-19       Impact factor: 2.953

3.  Peripartum pain management in opioid dependent women.

Authors:  A S Höflich; M Langer; R Jagsch; A Bäwert; B Winklbaur; G Fischer; A Unger
Journal:  Eur J Pain       Date:  2012-04       Impact factor: 3.931

4.  (R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy.

Authors:  Andrea L Gordon; Olga V Lopatko; Andrew A Somogyi; David J R Foster; Jason M White
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

5.  Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 2: special populations.

Authors:  Meldon Kahan; Lynn Wilson; Angela Mailis-Gagnon; Anita Srivastava
Journal:  Can Fam Physician       Date:  2011-11       Impact factor: 3.275

6.  Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention.

Authors:  Amber M Holbrook; Hendree E Jones; Sarah H Heil; Peter R Martin; Susan M Stine; Gabriele Fischer; Mara G Coyle; Karol Kaltenbach
Journal:  Drug Alcohol Depend       Date:  2013-03-21       Impact factor: 4.492

7.  Psychopharmacologic management of opioid-dependent women during pregnancy.

Authors:  Peter R Martin; Amelia M Arria; Gabriele Fischer; Karol Kaltenbach; Sarah H Heil; Susan M Stine; Mara G Coyle; Peter Selby; Hendrée E Jones
Journal:  Am J Addict       Date:  2009 Mar-Apr

8.  Respiratory effects of chronic in utero methadone or morphine exposure in the neonatal guinea pig.

Authors:  Rosemary T Nettleton; Michael Wallisch; George D Olsen
Journal:  Neurotoxicol Teratol       Date:  2008-03-21       Impact factor: 3.763

9.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

Review 10.  Practical considerations for the clinical use of buprenorphine.

Authors:  Hendree E Jones
Journal:  Sci Pract Perspect       Date:  2004-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.